NEW LOGO(large_trans_solo).png

  • HOME

  • ABOUT

    • LEADERSHIP
    • ADVISORS

  • OUR PROGRAM

    • NASH
    • ASK1
    • ASK1 inhibitors in NASH
    • SRT-015

  • PUBLICATIONS

  • NEWS

    • Jun 23, 2021
    • Nov 16, 2020
    • Nov 2, 2020
    • Nov 9, 2018

  • CONTACT

  • More

    Use tab to navigate through the menu items.
    >

    NEWS

    Seal Rock Therapeutics Announces Initiation of Phase 1 Clinical Trial of ASK1 Inhibitor SRT-015 for NASH

    June 23, 2021

    Read More  |

    Download PDF

    Seal Rock Therapeutics Presents Data Highlighting Superior Efficacy of ASK1 Inhibitor, SRT-015, to Selonsertib for NASH

    Nov 16, 2020  |

    Read More  |

    Download PDF

    FINAL Sealrock AASLD press release 11_16

    Seal Rock Therapeutics Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2020

    Nov 2, 2020  | 

    Read More  |

    Download PDF

    Nov 2 2020 Seal Rock Therapeutics Releas

    Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in NASH

    Nov 9, 2018  |

    Read More  |

    Download PDF

    Nov 9 2018 Seal Rock Therapeutics Releas
    SRT FIH PR june 23 2021.pdf

    • HOME

    • ABOUT

      • LEADERSHIP
      • ADVISORS

    • OUR PROGRAM

      • NASH
      • ASK1
      • ASK1 inhibitors in NASH
      • SRT-015

    • PUBLICATIONS

    • NEWS

      • Jun 23, 2021
      • Nov 16, 2020
      • Nov 2, 2020
      • Nov 9, 2018

    • CONTACT

    • More

      Use tab to navigate through the menu items.

      Seal Rock Therapeutics - 500 Yale Ave N, Seattle, WA 98109, USA - info@sealrocktx.com - 206.401.5086